46 completed, 10 unknown, 5 terminated, 3 active not recruiting. 27 Phase 4, 17 Phase 3, 16 Phase 2, 6 Phase 1, 2 Not applicable.
Follow Advagraf: new trials by email Literature Review of Advagraf trials Research Report on Advagraf
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tacrolimus C:D Ratio Measured in Renal Transplant Recipients Treated With Once-daily Prolonged-release Drugs Tacrolimus Pill, Tacrolimus capsule - Immunosuppression | Phase 4 | Recruiting | Edward Geissler | 300 | 2024-03-09 | 2024-05-16 |
| Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft Purified regulatory T-cells (Treg) plus CD34+ HSPC, Fludarabine, Melphalan - Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies | Phase 1 | Active not recruiting | Stanford University | 66 | 2021-09-07 | 2026-05-12 |
| Bioavailability and Practicability of Envarsus Versus Advagraf in Liver Transplant Recipients Tacrolimus Pill, Tacrolimus capsule - Prophylaxis Against Liver Transplant Rejection | Phase 4 | Active not recruiting | Edward Geissler | 268 | 2020-12-23 | 2025-04-06 |
| The New LC-MS/MS Method for Determination of Unbound Tacrolimus in Plasma Tacrolimus, Unbound tacrolimus measurement, CYP3A4 and CYP3A5 genotyping - Immunosuppression, Kidney Transplant Rejection | Unknown | National Science Centre, Poland | 380 | 2020-08-01 | 2022-04-22 | |
| Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients Tacrolimus immediate-release formulation, Tacrolimus prolonged-release formulation, Induction therapy - Kidney Transplant | Phase 4 | Completed | Astellas Pharma China, Inc. | 284 | 2018-10-21 | 2024-10-31 |
| Comparison of Safety and Efficacy of Two Variants of Prolonged - Released Tacrolimus (Advagraf vs. Envarsus ) in Patients After Liver Transplantation : Single Center Randomised Control Trial Envarsus, Advagraf - Liver Transplant Rejection, Immunosuppression | Not applicable | Unknown | Medical University of Warsaw | 200 | 2018-07-09 | 2018-07-27 |
| Sirolimus-based Immunosuppression Treatment Regimen for Liver Transplantation Tacrolimus, Tacrolimus (Tacrolimus elimination), Sirolimus - Liver Transplantation | Phase 2 / Phase 3 | Unknown | Southern Medical University, China | 130 | 2018-05-01 | 2018-04-18 |
| A Study to Compare the Finger Prick Whole Blood MITRA Assay Method With the Established Venepuncture Whole Blood Method for Quantitative Determination of Tacrolimus Blood Concentrations in Transplant Patients tacrolimus - Kidney Transplantation, Liver Transplantation | Phase 4 | Completed | Astellas Pharma Europe Ltd. | 80 | 2018-03-20 | 2018-10-15 |
| Efficacy and Safety of a Reduced Immunosuppression vs. Standard Triple Therapy in Senior Renal Transplant Recipients Reduced immunosuppression, Tacrolimus, mycophenolate - Immunosuppression After Renal Transplantation | Phase 4 | Unknown | Klemens Budde | 400 | 2017-12-01 | 2017-08-09 |
| A Study of Patient Adherence and Convenience to Immunosuppressive Agents in Newly Liver Transplant Advagraf, Prograf - Liver Transplantation | Phase 4 | Unknown | Chang Gung Memorial Hospital | 150 | 2017-11-23 | 2020-06-05 |
| Evaluate the Efficacy and Safety of the ADVAGRAF® Advagraf - Evidence of Liver Transplantation | Phase 4 | Completed | Linical Korea | 101 | 2016-11-01 | 2021-02-21 |
| To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients Tacrolimus, Tacrolimus immediate release - Kidney Transplantation | Phase 4 | Completed | Astellas Pharma Global Development, Inc. | 599 | 2016-09-09 | 2024-12-18 |
| Incidence of Non Adherence to Treatment With Once-daily Formulation of Tacrolimus Tacrolimus BID, Advagraf QD - Medication Adherence | Phase 3 | Unknown | Rabin Medical Center | 60 | 2016-08-01 | 2016-07-12 |
| Influence of CYP3A5 Polymorphism on Liver Function Abnormality and the Trough Level Change After Conversion Advagraf - Liver Dysfunction | Phase 4 | Unknown | Seoul National University Hospital | 60 | 2016-07-01 | 2016-08-31 |
| Twice-daily Tacrolimus and Everolimus Convert to Once-daily Tacrolimus and Everolimus in Liver Transplant Recipient Tacrolimus and Everolimus - Liver Transplantation | Phase 4 | Completed | Chang Gung Memorial Hospital | 10 | 2016-01-01 | 2020-06-05 |
| Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With Advanced Cutaneous T Cell Lymphoma Fludarabine, Total-Body Irradiation, T Cell-Depleted Donor Lymphocyte Infusion - Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides and Sezary Syndrome | Phase 1 | Withdrawn | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2015-11-20 | 2025-05-02 | |
| Global, Multicentre, Non Interventional Advagraf Conversion Registry in Kidney Transplant Patients Tacrolimus - Kidney Transplantation | Completed | Astellas Pharma Europe Ltd. | 4430 | 2015-03-05 | 2024-10-31 | |
| Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant Fludarabine Phosphate, Melphalan, Intensity-Modulated Radiation Therapy - Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia | Phase 1 | Suspended | University of Chicago | 30 | 2014-12-05 | 2026-03-30 |
| Slow and Low Start of a Tacrolimus Once Daily Immunosuppressive Regimen Advagraf - Renal Failure, Renal Insufficiency | Phase 3 | Unknown | Technische Universität Dresden | 400 | 2014-09-01 | 2022-08-03 |
| A Multicenter Study in Liver Transplant Patients Converted From Prograf® to Advagraf® During the First Post-transplantation Year Tacrolimus - Liver Transplantation | Completed | Astellas Pharma S.A.S. | 398 | 2014-06-18 | 2024-10-21 |
Showing 20 of 70. Sign in to see all of them.
Leukemia, Myeloid, Acute (6) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Hematologic Neoplasms (5) · Lymphoma, Non-Hodgkin (5) · Multiple Myeloma (5) · Hodgkin Disease (4) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Blast Crisis (3) · Burkitt Lymphoma (3) · Congenital Abnormalities (3) · Graft vs Host Disease (3) · Kidney Diseases (3) · Leukemia (3) · Leukemia, Myeloid, Accelerated Phase (3) · Lymphoma, B-Cell, Marginal Zone (3)
Astellas Pharma Inc (14) · Astellas Pharma Europe Ltd. (7) · Astellas Pharma Korea, Inc. (5) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (5) · Fred Hutchinson Cancer Center (3) · Astellas Pharma China, Inc. (2) · Chang Gung Memorial Hospital (2) · Edward Geissler (2) · Mayo Clinic (2) · Seoul National University Hospital (2) · Sun Yat-sen University (2) · Astellas Pharma Global Development, Inc. (1) · Astellas Pharma S.A.S. (1) · Barbara Ann Karmanos Cancer Institute (1) · City of Hope Medical Center (1)
United States (18) · France (14) · Germany (14) · South Korea (13) · Belgium (11) · Italy (11) · Poland (11) · United Kingdom (11) · Czechia (10) · Canada (9) · Austria (8) · China (8) · Hungary (8) · Netherlands (8) · Spain (8)
Dolores Grosso, DNP, CRNP (3) · Neal Flomenberg, MD (3) · Yu Xueqing, MD (2) · Adam G McLean, MA DPhil (1) · Bernhard Banas, MD (1) · Brenda Sandmaier (1) · Chin-Yuan Lee (1) · Christian Hugo, MD, PhD (1) · Christian Hugo, Prof. Dr. (1) · Claudio Anasetti, MD (1)
PMID 36094829, PMID 10071354, PMID 11003346, PMID 11072057, PMID 16468960, PMID 18431244, PMID 18510632, PMID 19715867, PMID 20534291, PMID 20534292, PMID 20840481, PMID 21868572, PMID 21958123, PMID 22211928, PMID 22689677, PMID 2305467, PMID 23714399, PMID 25048494, PMID 25085357, PMID 26053664, PMID 26151607, PMID 26256081, PMID 27266721, PMID 27547871, PMID 27871759, PMID 28817434, PMID 30098071, PMID 30582281, PMID 31029086, PMID 32499241, PMID 32911703, PMID 35007144, PMID 37170284, PMID 37391381, PMID 39082471, PMID 39382091, PMID 39739990, PMID 40197799
2008 (2), P01CA018029 (2), P30CA015704 (2), 2005 (1), 2014 (1), 2017 (1), 2018 (1), 2023 (1), P30CA014599 (1), P30CA022453 (1)